Because some molecular subtypes of endometrial cancer are significantly associated with lymph node metastasis—the P53-abnormal group demonstrates the highest incidence of nodal involvement, whereas the POLE-mutated group has the lowest [26,27]—such molecular classification has become a promising factor with which to tailor surgical treatment. Here, TP53 is linked to metastatic malignant neoplasm in the lymph nodes.